228 related articles for article (PubMed ID: 19759137)
1. Chloroquine administration does not prevent Nipah virus infection and disease in ferrets.
Pallister J; Middleton D; Crameri G; Yamada M; Klein R; Hancock TJ; Foord A; Shiell B; Michalski W; Broder CC; Wang LF
J Virol; 2009 Nov; 83(22):11979-82. PubMed ID: 19759137
[TBL] [Abstract][Full Text] [Related]
2. Combined chloroquine and ribavirin treatment does not prevent death in a hamster model of Nipah and Hendra virus infection.
Freiberg AN; Worthy MN; Lee B; Holbrook MR
J Gen Virol; 2010 Mar; 91(Pt 3):765-72. PubMed ID: 19889926
[TBL] [Abstract][Full Text] [Related]
3. Simulating henipavirus multicycle replication in a screening assay leads to identification of a promising candidate for therapy.
Porotto M; Orefice G; Yokoyama CC; Mungall BA; Realubit R; Sganga ML; Aljofan M; Whitt M; Glickman F; Moscona A
J Virol; 2009 May; 83(10):5148-55. PubMed ID: 19264786
[TBL] [Abstract][Full Text] [Related]
4. Developments towards effective treatments for Nipah and Hendra virus infection.
Bossart KN; Broder CC
Expert Rev Anti Infect Ther; 2006 Feb; 4(1):43-55. PubMed ID: 16441208
[TBL] [Abstract][Full Text] [Related]
5. Henipavirus pathogenesis and antiviral approaches.
Mathieu C; Horvat B
Expert Rev Anti Infect Ther; 2015 Mar; 13(3):343-54. PubMed ID: 25634624
[TBL] [Abstract][Full Text] [Related]
6. A treatment for and vaccine against the deadly Hendra and Nipah viruses.
Broder CC; Xu K; Nikolov DB; Zhu Z; Dimitrov DS; Middleton D; Pallister J; Geisbert TW; Bossart KN; Wang LF
Antiviral Res; 2013 Oct; 100(1):8-13. PubMed ID: 23838047
[TBL] [Abstract][Full Text] [Related]
7. Favipiravir (T-705) protects against Nipah virus infection in the hamster model.
Dawes BE; Kalveram B; Ikegami T; Juelich T; Smith JK; Zhang L; Park A; Lee B; Komeno T; Furuta Y; Freiberg AN
Sci Rep; 2018 May; 8(1):7604. PubMed ID: 29765101
[TBL] [Abstract][Full Text] [Related]
8. A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute nipah virus infection.
Bossart KN; Zhu Z; Middleton D; Klippel J; Crameri G; Bingham J; McEachern JA; Green D; Hancock TJ; Chan YP; Hickey AC; Dimitrov DS; Wang LF; Broder CC
PLoS Pathog; 2009 Oct; 5(10):e1000642. PubMed ID: 19888339
[TBL] [Abstract][Full Text] [Related]
9. Heparan sulfate-dependent enhancement of henipavirus infection.
Mathieu C; Dhondt KP; Châlons M; Mély S; Raoul H; Negre D; Cosset FL; Gerlier D; Vivès RR; Horvat B
mBio; 2015 Mar; 6(2):e02427. PubMed ID: 25759505
[TBL] [Abstract][Full Text] [Related]
10. Griffithsin Inhibits Nipah Virus Entry and Fusion and Can Protect Syrian Golden Hamsters From Lethal Nipah Virus Challenge.
Lo MK; Spengler JR; Krumpe LRH; Welch SR; Chattopadhyay A; Harmon JR; Coleman-McCray JD; Scholte FEM; Hotard AL; Fuqua JL; Rose JK; Nichol ST; Palmer KE; O'Keefe BR; Spiropoulou CF
J Infect Dis; 2020 May; 221(Supplement_4):S480-S492. PubMed ID: 32037447
[TBL] [Abstract][Full Text] [Related]
11. Hendra and nipah infection: pathology, models and potential therapies.
Vigant F; Lee B
Infect Disord Drug Targets; 2011 Jun; 11(3):315-36. PubMed ID: 21488828
[TBL] [Abstract][Full Text] [Related]
12. An antibody against the F glycoprotein inhibits Nipah and Hendra virus infections.
Dang HV; Chan YP; Park YJ; Snijder J; Da Silva SC; Vu B; Yan L; Feng YR; Rockx B; Geisbert TW; Mire CE; Broder CC; Veesler D
Nat Struct Mol Biol; 2019 Oct; 26(10):980-987. PubMed ID: 31570878
[TBL] [Abstract][Full Text] [Related]
13. Overview of Experimental Vaccines and Antiviral Therapeutics for Henipavirus Infection.
Satterfield BA; Mire CE; Geisbert TW
Methods Mol Biol; 2023; 2682():1-22. PubMed ID: 37610570
[TBL] [Abstract][Full Text] [Related]
14. Hendra and Nipah viruses: pathogenesis and therapeutics.
Eaton BT; Broder CC; Wang LF
Curr Mol Med; 2005 Dec; 5(8):805-16. PubMed ID: 16375714
[TBL] [Abstract][Full Text] [Related]
15. Containing the contagion: treating the virus that inspired the film.
Lee B
Sci Transl Med; 2011 Oct; 3(105):105fs6. PubMed ID: 22013121
[TBL] [Abstract][Full Text] [Related]
16. Detailed Molecular Biochemistry for Novel Therapeutic Design Against Nipah and Hendra Virus: A Systematic Review.
Bhattacharya S; Dhar S; Banerjee A; Ray S
Curr Mol Pharmacol; 2020; 13(2):108-125. PubMed ID: 31657692
[TBL] [Abstract][Full Text] [Related]
17. A Cross-Reactive Humanized Monoclonal Antibody Targeting Fusion Glycoprotein Function Protects Ferrets Against Lethal Nipah Virus and Hendra Virus Infection.
Mire CE; Chan YP; Borisevich V; Cross RW; Yan L; Agans KN; Dang HV; Veesler D; Fenton KA; Geisbert TW; Broder CC
J Infect Dis; 2020 May; 221(Suppl 4):S471-S479. PubMed ID: 31686101
[TBL] [Abstract][Full Text] [Related]
18. [Nipah and Hendra virus infectious diseases].
Yoneda M
Nihon Rinsho; 2016 Dec; 74(12):1973-1978. PubMed ID: 30550652
[TBL] [Abstract][Full Text] [Related]
19. Henipavirus outbreaks to antivirals: the current status of potential therapeutics.
Broder CC
Curr Opin Virol; 2012 Apr; 2(2):176-87. PubMed ID: 22482714
[TBL] [Abstract][Full Text] [Related]
20. Ribavirin therapy for Nipah virus infection.
Snell NJ
J Virol; 2004 Sep; 78(18):10211. PubMed ID: 15331756
[No Abstract] [Full Text] [Related]
[Next] [New Search]
